AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Teriparatide increases vertebral density and decreases the risk of spinal fractures in postmenopausal women regardless of their age, fracture history, or bone mineral density at baseline, reported Dr. Robert Marcus and his associates at Eli Lilly & Co., Indianapolis.
In a study funded by Lilly, which markets teriparatide as Forteo, the authors observed a dose-dependent increase in vertebral bone mineral density (BMD) after 3 months of treatment with teriparatide, compared with placebo. There also was a corresponding reduction in the incidence of new vertebral fractures.
Women who entered the study with the lowest BMD experienced the greatest percentage increase in BMD, but the absolute changes in BMD (as measured in grams per square centimeter) were similar m all of the treatment groups.
The study participants were 1,637 white women with a mean age of approximately 70 years. They had at least one moderate or two mild atraumatic vertebral fractures and a minimum of seven evaluable nonfractured vertebrae. Women with a hip or vertebral T score
The women were divided into three groups: 541 self-administered an injection of teriparatide in a dose of 20 [micro]g/day; 552 took 40 [micro]g teriparatide/day, and 544 injected a placebo. All of the women also took 1,000 mg/day of ...
Source: HighBeam Research, Teriparatide works regardless of age, fracture Hx. (Linked to Fewer...